ArticleJournal of global health2026
Global, regional, and national trends in blindness and vision loss, 1990-2021: a secondary ecological trend analysis based on modelled population estimates.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Ophthalmology Research Output Relative to Disease Burden and National Income, 2011-2021.Vision (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aimed to provide global, regional, and national estimates of the burden of blindness and vision loss from 1990 to 2021, stratified by cause, age, and sociodemographic index (SDI). Methods: This population-based study used data from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study 2021 (GBD) study, covering 1990 to 2021. It evaluates the burden of blindness and vision loss based on prevalence, age-standardised prevalence rate (ASPR), disability-adjusted life years (DALYs), age-standardised DALY rate (ASR of DALY), and average annual percent changes (AAPCs). Results: Globally, the ASPR of blindness and vision loss increased from 12 453.52 (95% uncertainty interval (UI) = 10 287.58, 15 226.09) in 1990 to 15 784.33 (95% UI = 12 761.44, 19 502.32) in 2021, with an AAPC of 0.85 (95% confidence interval (CI) = 0.7, 1.11, P < 0.001). In contrast, the ASR of DALYs remained stable, changing from 342.01 (95% UI = 237.87, 482.17) in 1990 to 342.78 (95% UI = 224.21, 503.61) in 2021, with an AAPC of 0.05 (95% CI = -0.04, 0.2, P = 0.298). Notably, near vision loss and cataract showed consistent increases, with AAPCs of 1.14 (95% CI = 0.94, 1.51, P < 0.001) and 0.25 (95% CI = 0.16, 0.33, P < 0.001), respectively. Blindness and vision loss prevalence was significantly higher in low and low-middle SDI regions compared to other SDI regions. Conclusions: Global blindness and vision loss increased from 1990 to 2021, while DALYs stayed stable. Prevention should be tailored by region, country, gender, cause, and age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.